8-K: Bullfrog AI Appoints Josh Blacher as New Chief Financial Officer Following Passing of Dane Saglio
Personnel Change Announcement
Bullfrog AI Holdings, Inc. has appointed Josh Blacher as its new Chief Financial Officer, effective immediately, following the passing of former CFO Dane Saglio.
Summary
- Bullfrog AI Holdings, Inc. has appointed Josh Blacher as its new Chief Financial Officer, effective December 17, 2024.
- This appointment follows the recent passing of the company's former CFO, Dane Saglio.
- Mr. Blacher will serve as an independent contractor through Danforth Advisors, LLC, with Bullfrog AI paying Danforth $525 per hour for his services.
- Danforth has the option to increase the hourly rate by up to 5% annually, starting January 1 of each year.
- Mr. Blacher has extensive experience in strategic finance and corporate development, particularly within the life sciences and biotech sectors.
- He has previously served as CFO for Predictive Oncology, Rampart Bioscience, and Excision BioTherapeutics, among others.
- Mr. Blacher will focus on enhancing the company's balance sheet, financial operations, and supporting strategic initiatives.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the appointment of an experienced CFO, but tempered by the circumstances of the previous CFO's passing and the use of a consulting agreement.
Positives
- The appointment of Josh Blacher brings a wealth of experience in strategic finance and corporate development to Bullfrog AI.
- Mr. Blacher's background includes successful oversight of SEC reporting and investor relations for both private and public companies.
- His experience in capital raising, operations, and profitability is expected to benefit Bullfrog AI.
- The company has secured a seasoned financial professional to help guide its financial strategy.
Negatives
- The appointment of a new CFO was necessitated by the untimely passing of the previous CFO, Dane Saglio.
- The company will be paying an hourly rate for the CFO's services through a consulting agreement, which may be more expensive than a direct hire.
Risks
- The transition to a new CFO could present challenges in maintaining financial continuity.
- The consulting agreement with Danforth Advisors, LLC, introduces a third party into the financial management structure.
- The hourly rate for the CFO's services is subject to potential annual increases, which could impact the company's expenses.
Future Outlook
The company expects the new CFO to enhance the company's balance sheet strength, financial operations, and support its strategic initiatives. The company also has forward looking statements regarding financial performance and projections, growth in revenue and earnings, and business prospects and opportunities.
Management Comments
- Vin Singh, CEO of Bullfrog AI, stated that Dane Saglio's contributions were immeasurable and that his wisdom, humility, and commitment will be deeply missed.
- Vin Singh also expressed gratitude to welcome Josh Blacher to the team, highlighting his extensive experience and leadership in financial strategy and corporate governance.
Industry Context
The appointment of a new CFO with extensive experience in the life sciences and biotech sectors aligns with Bullfrog AI's focus on drug development using artificial intelligence. This move is consistent with the industry trend of bringing in experienced financial leadership to support growth and strategic initiatives.
Comparison to Industry Standards
- The use of a consulting firm for CFO services is not uncommon in the biotech industry, especially for companies in early stages or during transitions.
- Companies like Predictive Oncology, Rampart Bioscience, and Excision BioTherapeutics, where Mr. Blacher previously served as CFO, are also in the life sciences and biotech space, indicating a relevant background.
- The hourly rate of $525 is within the range for experienced financial consultants, but the potential for annual increases should be monitored.
- The appointment of a CFO with experience in SEC reporting and investor relations is crucial for a publicly traded company like Bullfrog AI.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Dane Saglio | Josh Blacher | 2024-12-17 | Passing of previous CFO |
Stakeholder Impact
- Shareholders may view the appointment of an experienced CFO positively, potentially increasing investor confidence.
- Employees may experience a period of adjustment with the new CFO, but his experience could bring stability.
- Customers and partners may see the appointment as a sign of the company's commitment to financial stability and growth.
Next Steps
- Mr. Blacher will focus on enhancing the company's balance sheet strength and financial operations.
- Mr. Blacher will support the company's strategic initiatives.
- The company will continue to develop its AI-driven drug discovery platform.
Key Dates
| Date | Description |
|---|---|
| 2022-09 | Josh Blacher joined Danforth Advisors as an employee. |
| 2023-09 | Josh Blacher became Chief Financial Officer of Predictive Oncology as a consultant of Danforth. |
| 2024-12-12 | The Board of Directors of Bullfrog AI Holdings, Inc. appointed Josh Blacher as Chief Financial Officer. |
| 2024-12-13 | The Master Services Agreement between Bullfrog AI and Danforth Advisors, LLC was made effective. |
| 2024-12-17 | Bullfrog AI issued a press release announcing the appointment of Josh Blacher as CFO. |
Keywords
Chief Financial Officer, CFO, Josh Blacher, Danforth Advisors, Financial Strategy, Corporate Development, Life Sciences, Biotech, Financial Operations, SEC Reporting, Capital Raising, Bullfrog AI
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.